Only a smidgen of cancer patients who undergo surgery later participate in clinical trials to test new medications. Those who participate are younger than 65 years old, usually white and in the early stages, raising questions about the extent to which new drugs will be effective because trial subjects do not reflect patients in the wider population, according to a study in the Annals of Surgery.
